Table 2.
Comparison of baseline demographic and clinical characteristics between cases with and without intraocular inflammation after brolucizumab injection.
| Total | IOI (+) | IOI (−) | P value | |
|---|---|---|---|---|
| Number of eyes | 42 | 8 | 34 | |
| Age (years) | 74.9 ± 8.6 | 81.0 ± 7.9 | 73.4 ± 8.1 | 0.047 |
| Male | 35 (83.3%) | 4 (50.0%) | 31 (91.2%) | 0.017 |
| Best-corrected visual acuity (logMAR) | 0.24 ± 0.25 | 0.18 ± 0.12 | 0.25 ± 0.27 | 0.701 |
| Central macular thickness (µm) | 296 ± 109 | 275 ± 87 | 303 ± 110 | 0.543 |
| Central choroidal thickness (µm) | 264 ± 87 | 245 ± 75 | 269 ± 89 | 0.433 |
| Polypoidal lesions (+) | 23 (54.8%) | 6 (75.0%) | 17 (50.0%) | 0.190 |
IOI intraocular inflammation.